目的 探討CD44v6和nm23H1的mRNA表達(dá)與乳腺癌臨床病理參數(shù)及預(yù)后的關(guān)系及相關(guān)性。方法 應(yīng)用原位雜交和CSA免疫組化方法，對(duì)94例乳腺癌組織進(jìn)行CD44v6和nm23H1的mRNA檢測(cè)。 結(jié)果 CD44v6 mRNA陽(yáng)性表達(dá)及nm23H1 mRNA陰性表達(dá)均與乳腺癌的組織學(xué)分級(jí)、臨床分期、淋巴結(jié)轉(zhuǎn)移、復(fù)發(fā)和預(yù)后呈正相關(guān)。乳腺癌中CD44v6 mRNA表達(dá)與nm23H1 mRNA表達(dá)呈負(fù)相關(guān)。CD44v6 mRNA陽(yáng)性表達(dá)及nm23H1 mRNA陰性表達(dá)患者淋巴結(jié)轉(zhuǎn)移率高、生存率低。結(jié)論 CD44v6 mRNA表達(dá)與nm23H1 mRNA表達(dá)具有負(fù)調(diào)節(jié)的協(xié)同作用。聯(lián)合檢測(cè)兩種基因，能更準(zhǔn)確地判斷乳腺癌的轉(zhuǎn)移、預(yù)后狀態(tài)。
引用本文： 谷化平,倪燦榮,尚培中,詹溶洲. 乳腺癌組織CD44v6和nm23H1的mRNA表達(dá)及意義. 中國(guó)普外基礎(chǔ)與臨床雜志, 2001, 8(5): 307-309. doi: 復(fù)制
| 1. | 李樹玲. 中國(guó)常見惡性腫瘤診治規(guī)范 〔M〕. 北京: 北京醫(yī)科大學(xué)、中國(guó)協(xié)和醫(yī)科大學(xué)聯(lián)合出版社,1990∶59~60. |
| 2. | 倪燦榮, 朱明華, 馬大烈. 催化信號(hào)放大系統(tǒng)在原位雜交檢測(cè)中的應(yīng)用研究 〔Ｊ〕. 中國(guó)組織化學(xué)與細(xì)胞化學(xué)雜志, 2000; 9(1)∶110. |
| 3. | Emak G, Jemings T, Robinson L, et al. Restricted pattern of CD44 variant exon expression in human papillary thyroid carcinoma 〔Ｊ〕. Cancer Res, 1996; 56(5)∶1037. |
| 4. | Kainz C, Tempfer C, Kohlberger P, et al. Immunohistochemical detection of adhesion molecule CD44 splice variants in lymphnode metastasis of cervial cancer 〔Ｊ〕. Int J Cancer, 1997; 74（2）∶185. |
| 5. | Christopher J, Amil K. CD44 isoform expression in primary and metastatic pancreatic adenocarcinoma 〔Ｊ〕. Cancer Res, 1995; 55（4）∶1831. |
| 6. | Hennessy C, Henry JA, May FE, et al. Expression of the antimetastatic gene nm23 in human breast cancer: an association with good prognosis 〔Ｊ〕. J Natl Cancer Inst, 1991; 83(4)∶281. |
| 7. | Sreeg PS, Rosa AD, Flatow U, et al. nm23 and breast cancer metastasis 〔Ｊ〕. Breast Cancer Research and Treatment, 1993; 2(2)∶175. |
| 8. | Arai T, Yamshita T, Urano T, et al. Preferential reduction of nm23H1 gene product in metastatic tissue from papillary and follicuar carcinoma of thyroid 〔Ｊ〕. Mad Pathal, 1995; 8(3)∶252. |
- 1. 李樹玲. 中國(guó)常見惡性腫瘤診治規(guī)范 〔M〕. 北京: 北京醫(yī)科大學(xué)、中國(guó)協(xié)和醫(yī)科大學(xué)聯(lián)合出版社,1990∶59~60.
- 2. 倪燦榮, 朱明華, 馬大烈. 催化信號(hào)放大系統(tǒng)在原位雜交檢測(cè)中的應(yīng)用研究 〔Ｊ〕. 中國(guó)組織化學(xué)與細(xì)胞化學(xué)雜志, 2000; 9(1)∶110.
- 3. Emak G, Jemings T, Robinson L, et al. Restricted pattern of CD44 variant exon expression in human papillary thyroid carcinoma 〔Ｊ〕. Cancer Res, 1996; 56(5)∶1037.
- 4. Kainz C, Tempfer C, Kohlberger P, et al. Immunohistochemical detection of adhesion molecule CD44 splice variants in lymphnode metastasis of cervial cancer 〔Ｊ〕. Int J Cancer, 1997; 74（2）∶185.
- 5. Christopher J, Amil K. CD44 isoform expression in primary and metastatic pancreatic adenocarcinoma 〔Ｊ〕. Cancer Res, 1995; 55（4）∶1831.
- 6. Hennessy C, Henry JA, May FE, et al. Expression of the antimetastatic gene nm23 in human breast cancer: an association with good prognosis 〔Ｊ〕. J Natl Cancer Inst, 1991; 83(4)∶281.
- 7. Sreeg PS, Rosa AD, Flatow U, et al. nm23 and breast cancer metastasis 〔Ｊ〕. Breast Cancer Research and Treatment, 1993; 2(2)∶175.
- 8. Arai T, Yamshita T, Urano T, et al. Preferential reduction of nm23H1 gene product in metastatic tissue from papillary and follicuar carcinoma of thyroid 〔Ｊ〕. Mad Pathal, 1995; 8(3)∶252.